Business Description
Mainz Biomed NV
ISIN : NL0015000LC2
Description
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples.
Financial Strength
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.12 | |||||
| Equity-to-Asset | -0.49 | |||||
| Debt-to-Equity | -2 | |||||
| Debt-to-EBITDA | -0.33 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | N/A/9 | |||||
| Altman Z-Score | -21.7 | |||||
| Beneish M-Score | -5.84 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 9.4 | |||||
| 3-Year EBITDA Growth Rate | -310 | |||||
| 3-Year EPS without NRI Growth Rate | -212.9 | |||||
| 3-Year FCF Growth Rate | -229.6 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 25.27 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 114.71 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 29.37 | |||||
| 9-Day RSI | 41.23 | |||||
| 14-Day RSI | 44.73 | |||||
| 6-1 Month Momentum % | -76.56 | |||||
| 12-1 Month Momentum % | -90.91 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.24 | |||||
| Quick Ratio | 0.19 | |||||
| Cash Ratio | 0.1 | |||||
| Days Inventory | 476.58 | |||||
| Days Sales Outstanding | 44.5 | |||||
| Days Payable | 1952.66 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -21.8 | |||||
| Shareholder Yield % | -148.65 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 56.92 | |||||
| Operating Margin % | -2997.21 | |||||
| Net Margin % | -2934.82 | |||||
| FCF Margin % | -2664.74 | |||||
| ROE % | -1359.67 | |||||
| ROA % | -172.22 | |||||
| ROIC % | -201.97 | |||||
| 3-Year ROIIC % | -230.04 | |||||
| ROC (Joel Greenblatt) % | -800.75 | |||||
| ROCE % | -517.65 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 4.63 | |||||
| EV-to-EBIT | -0.54 | |||||
| EV-to-EBITDA | -0.56 | |||||
| EV-to-Revenue | 15.53 | |||||
| EV-to-Forward-Revenue | 5.94 | |||||
| EV-to-FCF | -0.58 | |||||
| Earnings Yield (Greenblatt) % | -185.19 | |||||
| FCF Yield % | -359.71 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Mainz Biomed NV Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 0.831 | ||
| EPS (TTM) (€) | -1.522 | ||
| Beta | 0 | ||
| Volatility % | 83.02 | ||
| 14-Day RSI | 44.73 | ||
| 14-Day ATR (€) | 0.031263 | ||
| 20-Day SMA (€) | 0.25785 | ||
| 12-1 Month Momentum % | -90.91 | ||
| 52-Week Range (€) | 0.173 - 3.18 | ||
| Shares Outstanding (Mil) | 25.59 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9999 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Mainz Biomed NV Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Mainz Biomed NV Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Mainz Biomed NV Frequently Asked Questions
What is Mainz Biomed NV(STU:4TO)'s stock price today?
The current price of STU:4TO is €0.24. The 52 week high of STU:4TO is €3.18 and 52 week low is €0.17.
When is next earnings date of Mainz Biomed NV(STU:4TO)?
The next earnings date of Mainz Biomed NV(STU:4TO) is 2024-11-15 Est..
Does Mainz Biomed NV(STU:4TO) pay dividends? If so, how much?
Mainz Biomed NV(STU:4TO) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers